Related Experiment Video
Updated: Sep 3, 2025

Measuring the Carotid to Femoral Pulse Wave Velocity Cf-PWV to Evaluate Arterial Stiffness
Published on: May 3, 2018
Association Between Plasma Fibulin-1 and Brachial-Ankle Pulse Wave Velocity in Arterial Stiffness
Mandi Luo1, Dan Yan1, Xiaolu Liang1
1Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Insights
Arterial stiffness, a key factor in cardiovascular disease, is linked to elevated plasma fibulin-1 levels. This study identifies fibulin-1 as a potential biomarker and independent risk factor for arterial stiffness.
Area of Science:
- Cardiovascular Research
- Proteomics
- Biomarker Discovery
Background:
- Arterial stiffness is a primary driver of cardiovascular diseases (CVD) and a significant independent predictor of CVD risk.
- Early detection and intervention are crucial for managing the global burden of CVD.
- Extracellular matrix (ECM) remodeling is a key mechanism in arterial stiffness, with ECM proteins detectable in plasma.
Purpose of the Study:
- To investigate plasma proteomic differences between individuals with high and normal arterial stiffness.
- To identify specific extracellular matrix (ECM) proteins associated with arterial stiffness.
- To validate fibulin-1 as a potential biomarker for arterial stiffness.
Main Methods:
- Quantitative proteomics (iTRAQ) was employed to compare plasma proteins in high (baPWV ≥ 1,400 cm/s) versus normal (baPWV < 1,400 cm/s) arterial stiffness groups (n=6 each).
- Nine differentially expressed ECM proteins were identified, with fibulin-1 showing the highest fold-change.
- Plasma fibulin-1 levels were confirmed using enzyme-linked immunosorbent assay (ELISA) in larger cohorts (n=112 normal, n=72 high stiffness).
Main Results:
- Proteomics identified 169 differentially expressed proteins (DEPs), including nine up-regulated ECM proteins.
- Fibulin-1 exhibited the highest fold-change (FC = 3.7, p < 0.0001) in the high arterial stiffness group.
- ELISA confirmed significantly higher plasma fibulin-1 concentrations in the high stiffness group (12.69 ± 0.89 μg/ml) compared to the normal group (9.84 ± 0.71 μg/ml, p < 0.05).
- Fibulin-1 showed a positive correlation with brachial-ankle pulse wave velocity (baPWV) (r = 0.32, p < 0.01), with a stronger correlation in the high stiffness group (r = 0.64, p < 0.0001).
- Multiple regression analysis identified fibulin-1 as a significant determinant of increased baPWV (R² = 0.635, p = 0.001).
Conclusions:
- Plasma fibulin-1 levels are significantly elevated in individuals with high arterial stiffness.
- Fibulin-1 is positively correlated with baPWV and emerges as an independent risk factor for arterial stiffness.
- Fibulin-1 holds potential as a valuable biomarker for early detection and management of arterial stiffness and associated cardiovascular risks.
Abstract:
Arterial stiffness forms the basis of cardiovascular diseases (CVD) and is also an independent predictor of CVD risk. Early detection and intervention of arterial stiffness are important for improving the global burden of CVD. Pulse wave velocity (PWV) is the gold standard for assessing arterial stiffness and the molecular mechanism of arterial stiffness remains to be studied. Extracellular matrix (ECM) remodeling is one of the major mechanisms of arterial stiffness. Partial quantitative changes of ECM proteins can be detected in plasma. Therefore, we examined the hypothesis that a discovery proteomic comparison of plasma proteins between high arterial stiffness (baPWV ≥ 1,400 cm/s) and normal arterial stiffness (baPWV < 1,400 cm/s) populations might identify relevant changed ECM proteins for arterial stiffness. Plasma samples were randomly selected from normal arterial stiffness (n = 6) and high arterial stiffness (n = 6) people. Isobaric tags for relative and absolute quantitation (iTRAQ) based quantitative proteomics technique was performed to find a total of 169 differentially expressed proteins (DEPs). Nine ECM proteins were included in all DEPs and were all up-regulated proteins. Fibulin-1 had the highest statistically fold-change (FC = 3.7, p < 0.0001) in the high arterial stiffness population compared with the control group during the nine ECM proteins. The expression of plasma fibulin-1 in normal arterial stiffness (n = 112) and high arterial stiffness (n = 72) populations was confirmed through enzyme-linked immunosorbent assay (ELISA). Similarly, ELISA results showed that plasma concentrations of fibulin-1 in the high arterial stiffness group were higher than those in the normal arterial stiffness group (12.69 ± 0.89 vs. 9.84 ± 0.71 μg/ml, p < 0.05). Univariate analysis of fibulin-1 with brachial-ankle pulse wave velocity (baPWV) indicated that fibulin-1 was positively correlated with baPWV in all participants (r = 0.32, p < 0.01) and a stronger positive correlation between baPWV and fibulin-1 in high arterial stiffness group (r = 0.64, p < 0.0001) was found. Multiple regression analysis of factors affecting baPWV showed that fibulin-1 was also a significant determinant of the increased ba-PWV (R = 0.635, p = 0.001). Partial correlation analysis showed that baPWV increased with the growth of plasma fibulin-1(r = 0.267, p < 0.001). In conclusion, our results demonstrated that fibulin-1 is positively correlated with ba-PWV and an independent risk factor for arterial stiffness.
Related Concept Videos
Assessment of blood pressure in brachial artery(one-step method)
Prepare for the Procedure:
Sites for measruring blood pressure
The Brachial Artery: Primary Site for Blood Pressure Measurement
Assessment of blood pressure in brachial artery(two-step method)
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Pulse
The pulse serves as a clinical...
Assessing Blood pressure in the Leg
Preparation:

